Proteostasis Acquires Two Harvard Protein Licenses

Cambridge-based biotech Proteostasis has licensed technology coming out of Harvard University labs studying the ubiquitin-proteasome pathway. The company plans to develop small molecule regulators of this pathway that promote the folding and/or clearance of aggregation prone proteins associated with AD, PD and other neurodegenerative diseases.

Click here to read more.

Share this: